About Ascelia Pharma

Company Description

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

About Orviglance (Mangoral)
Orviglance* (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function.

About Oncoral
Oncoral is a novel oral irinotecan tablet in development. Irinotecan is a chemotherapy with established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Year founded


Served area



Hyllie Boulevard 34, 21532 Malmö – Sweden

Shareholder information

Shares outstanding



Jan. 1, 2000

Stock exchange(s)

Nasdaq Stockholm



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.